Publications
101
Citations
919
Est. group size
~34
Recurring co-author estimate
Active years
43
Publishing since 1984
Elizabeth M. Grainger's publication record centers on clinical trials for lung cancer treatment, particularly non-small cell lung cancer (NSCLC), examining drug combinations involving chemoradiotherapy and immunotherapy agents. The work appears to involve large multi-site trial collaborations rather than laboratory-based research, based on the trial-report style of the listed publications and large estimated co-author group.
Publication output has grown over the last decade, with a notable increase in 2023 compared to earlier years, though recent years show some fluctuation.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- OA12.03 Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA Study
Journal of Thoracic Oncology · 2024
- 971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)
Annals of Oncology · 2022
- P2.01-05 MAGELLAN: Phase 1B Study of Durvalumab with Novel Oncology Therapies, With/Without Chemotherapy, in Untreated Stage IV NSCLC
Journal of Thoracic Oncology · 2019
- Medicine & Science in Sports & Exercise×9
- Journal of the Academy of Nutrition and Dietetics×7
- Current Developments in Nutrition×7
- Cancer Research×4
- Journal of Thoracic Oncology×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile